. 2015 Oct 16;29(6):1479–1487. doi: 10.1111/jvim.13639

Table 3.

UP/C changes from baseline by treatment and study day for the PPS population

Treatment	Day	N	Mean	SD	Median	Range	IQ Range	P‐value
Benazepril	7	87	−0.06	0.25	0.0	−1.4 to 1.0	0.10	.040
	30	88	−0.06	0.28	0.0	−1.5 to 0.5	0.15	.023
	60	87	−0.07	0.38	0.0	−1.6 to 1.1	0.10	.046
	90	86	+0.06	0.61	0.0	−1.5 to 3.5	0.20	.072
	120	85	+0.06	0.77	−0.1	−1.6 to 5.2	0.20	.143
	180	76	−0.02	0.48	0.0	−1.5 to 2.3	0.20	.136
Telmisartan	7	80	−0.07	0.28	−0.1	−1.7 to 1.0	0.10	<.0001^a
	30	83	−0.08	0.26	−0.1	−1.6 to 0.5	0.10	<.0001^a
	60	82	−0.09	0.33	−0.1	−1.7 to 0.8	0.10	.0002^a
	90	83	−0.08	0.31	−0.1	−1.4 to 1.3	0.20	<.0001^a
	120	75	−0.02	0.51	−0.1	−1.6 to 2.4	0.20	.002^a
	180	72	−0.05	0.31	0.0	−1.1 to 1.1	0.10	.016^a

The P‐values are adjusted for multiplicity by the Bonferroni–Holm procedure (P‐values sorted from lowest to highest and compared to the adjusted P‐values (ie, .0083; .01; .0125; .016; .025; .05).

Significantly different from baseline.